What it's for (Indications)
- Nepafenac ophthalmic suspension is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation associated with cataract surgery.
- It is also specifically indicated for the reduction of the risk of macular edema associated with cataract surgery in patients with diabetes mellitus.
- This medication plays a crucial role in managing post-operative ocular discomfort and inflammatory responses, thereby contributing to improved visual outcomes and patient recovery following ophthalmic procedures.
- Its utility extends particularly to vulnerable patient populations, such as those with diabetes, where complications like macular edema are a significant concern.
- The recommended use typically involves initiation prior to surgery and continuation during the post-operative period to maximize therapeutic benefit and minimize complications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the treatment of pain and inflammation associated with cataract surgery, nepafenac 0.1% ophthalmic suspension is typically instilled one drop into the affected eye(s) three times daily, beginning 1 day prior to cataract surgery, continued on the day of surgery, and for the first 2 weeks of the post-operative period. For the reduction of risk of macular edema associated with cataract surgery in diabetic patients, nepafenac 0.3% ophthalmic suspension is recommended, one drop into the affected eye(s) once daily, beginning 1 day prior to surgery, continued on the day of surgery, and for up to 60 days post-operatively, as directed by an ophthalmologist. It is crucial to follow the prescribed regimen precisely and avoid prolonged use beyond the recommended duration without medical consultation. Patients should shake the bottle well before each use. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions associated with nepafenac ophthalmic suspension include blurred vision, foreign body sensation, sticky sensation, ocular pain, photophobia, lacrimation, dry eye, conjunctival edema, punctate keratitis, and headache.
- These are generally mild to moderate and transient.
- Less common but more serious adverse events can include corneal thinning, erosion, ulceration, or perforation, particularly in patients with pre-existing corneal epithelial defects, diabetes, or other ocular surface diseases.
- Other potential serious reactions involve increased intraocular pressure, allergic conjunctivitis, and severe eye irritation.
- Patients should report any persistent or worsening ocular symptoms, significant discomfort, or changes in vision immediately to their ophthalmologist, as these may indicate a need for treatment discontinuation or further evaluation.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Corneal Effects and Delayed Healing:** While nepafenac ophthalmic suspension does not carry a formal FDA Black Box Warning, clinicians and patients should be acutely aware of significant safety concerns, particularly regarding corneal health and the potential for delayed healing. The use of topical NSAIDs, including nepafenac, can lead to or exacerbate corneal adverse events such as thinning, erosion, ulceration, and even perforation, which may be sight-threatening. This risk is notably elevated in patients undergoing complicated ocular surgeries, those with pre-existing corneal denervation, epithelial defects, diabetes mellitus, ocular surface diseases (e.g., severe dry eye), rheumatoid arthritis, or individuals undergoing repeat ocular surgeries within a short timeframe. Concomitant use with topical corticosteroids may further increase this risk. Patients should be closely monitored for signs of corneal breakdown. If such events occur, discontinuation of nepafenac should be considered, and appropriate ophthalmic management initiated promptly. Prolonged use beyond the recommended duration should be avoided, as it may increase the likelihood and severity of these adverse effects.
- Nepafenac, like other topical NSAIDs, can slow or delay healing of corneal wounds.
- The concomitant use of topical NSAIDs and topical corticosteroids may increase the potential for healing problems.
- There is a potential for cross-sensitivity to aspirin, phenylacetic acid derivatives, and other NSAIDs.
- Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
- Use of topical NSAIDs for prolonged periods may result in corneal adverse events, including corneal breakdown, thinning, erosion, ulceration, or perforation.
- Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.
- g.
- , dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period may be at increased risk.
- Discontinuation of the medication should be considered if evidence of corneal breakdown is observed.
- Contact lens wear should be avoided during treatment.
How it Works (Mechanism of Action)
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a prodrug. Upon topical ocular administration, it rapidly penetrates the cornea. Once inside the ocular tissues, nepafenac is metabolized by hydrolases to its active metabolite, amfenac, which is a potent inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. By inhibiting these enzymes, amfenac effectively blocks the biosynthesis of prostaglandins. Prostaglandins are lipid compounds that play a crucial role as mediators of inflammation, pain, and miosis (pupil constriction) within the eye. The inhibition of prostaglandin synthesis by amfenac thus reduces ocular inflammation and pain associated with cataract surgery, and it contributes to the reduction of macular edema risk in diabetic patients post-operatively. This targeted local action minimizes systemic exposure while maximizing therapeutic effect in the eye.